Gulnar Hafiz

Medicine & Life Sciences

1. Macular Edema 100%
2. Retinal Vein Occlusion 80%
3. Ranibizumab 72%
4. Vascular Endothelial Growth Factor A 52%
5. Visual Acuity 43%
6. Eye 34%
7. Edema 29%
8. Macular Degeneration 28%
9. Fluocinolone Acetonide 26%
10. Choroidal Neovascularization 20%
11. Injections 18%
12. Acetylcysteine 18%
13. combretastatin 15%
14. Permeability 15%
15. Dexamethasone 13%
16. Light Coagulation 12%
17. Lasers 12%
18. Controlled Clinical Trials 12%
19. Central Serous Chorioretinopathy 11%
20. Mecamylamine 11%
21. Safety 10%
22. Octreotide 9%
23. Placebos 9%
24. Interleukin-18 9%
25. Bevacizumab 9%
26. Metabolomics 9%
27. Therapeutics 8%
28. Ocular Vision 8%
29. prednisolone acetate 8%
30. Hispanic Americans 7%
31. Cataract 7%
32. Optical Coherence Tomography 7%
33. Phosphates 7%
34. Tetrahydrocortisol 7%
35. Oxidative Stress 6%
36. Health Care Outcome Assessment 6%
37. Proteins 6%
38. Hepatocyte Growth Factor 6%
39. Nicotinic Receptors 6%
40. Steroids 6%
41. Fluorescein 6%
42. Endocrine Glands 5%
43. Intravenous Infusions 5%
44. Blood Vessels 5%
45. persephin 5%
46. Glutathione Disulfide 5%